Crossmark

ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

Crossref DOI link: https://doi.org/10.1245/s10434-022-11621-1

Published Online: 2022-04-03

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ushida, Yuta

Inoue, Yosuke

Oba, Atsushi

Mie, Takafumi

Ito, Hiromichi

Ono, Yoshihiro

Sato, Takafumi

Ozaka, Masato

Sasaki, Takashi

Saiura, Akio

Sasahira, Naoki

Takahashi, Yu
License Information

Text and Data Mining valid from 2022-04-03

Version of Record valid from 2022-04-03
More Information

Article History

Received: 2 March 2022

Accepted: 4 March 2022

First Online: 3 April 2022

Declarations

:

: Masato Ozaka received honoraria from Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. Takashi Sasaki received honoraria from Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. Naoki Sasahira received honoraria from Taiho Pharmaceutical Co., Ltd. The remaining authors declare no conflict of interest.

Document is current

Any future updates will be listed below